The Norwegian life sciences landscape is currently undergoing a systemic transition, evolving from a research-intensive academic environment into a globally integrated commercial powerhouse. This metamorphosis is facilitated by a unique confluence of high-trust public health data, a robust sovereign wealth environment and a maturing infrastructure of specialised clusters such as Norway Health Tech, the Oslo Cancer Cluster and Aleap. As the global healthcare market increasingl